ABOUT SAMSUNG BIOLOGICS
Samsung Biologics is a full-service provider offering development and cGMP manufacturing services. We deliver a broad range of services from development and manufacturing to fill and finish, covering both clinical molecules and commercial products. Established in April 2011, Samsung Biologics will transform the global healthcare industry over the next decade through our quality, technology and innovation. Our facilities are custom designed for monoclonal & recombinant production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services (characterization, comparability, IPC, lot release & stability), and clinical and commercial bulk cGMP manufacturing of drug substance and drug product. We also provide quality assurance and quality control services, as well as worldwide regulatory compliance standards & support for our customers. We are centrally located in the heart of Asia, within 20 minutes of Incheon International Airport.
SERVICES
Samsung Biologics is a reliable partner for seamless tech transfers, clinical and commercial manufacturing, aseptic fill/finish, and analytical testing. Committed to partnership, you will have a dedicated project management team walking you through your product’s entire development and manufacturing journey. We are committed to operational excellence in cGMP manufacturing and quality assurance.
As your most qualified world’s leading CDMO partner, Samsung Biologics delivers your success to IND & BLA Faster & Better with maximum flexibility. We promise the Best.
Samsung Biologics provides an ‘End-to-End’ biosafety testing service for CMO / CDO clients. CRO services cover development stage to DS products for lot release tests of Mycoplasma & Virus detection. Our service is expanding to Cell bank manufacturing, Cell line characterization and Viral clearance study.
CONTACT INFORMATION
Samsung Biologics
300 Songdo Bio Way, Yeonsu-gu
Incheon, 21987
KOREA, REPUBLIC OF
Phone: +82 32 455 3114
Contact: Jinyong Kim
BROCHURES
FEATURED ARTICLES
- Monoclonal Antibody Manufacturing: Build Or Outsource?
- Best Practices For Biopharmaceutical Technology Transfer: Facility Fit And Process Gap Assessments
- How Integrated Market Intelligence Improves Aseptic Fill/Finish Outcomes
- Critical Success Factors For Cell Line Development
- Beyond COVID-19: How Localization Strengthens Supply Chains
- How The Integration Of CDMO And CRO Services Benefits Everyone
- The Challenges Of Biopharmaceutical Quality
- Ensuring A Successful Technology Transfer
- Embracing Necessary Digital Transformation In Biomanufacturing
- Dedicated To Digitalization
- It Depends: The Real Answer To The Single-Use Or Stainless-Steel Question
- Process Optimization And Characterization For Product Safety, Quality
- Strategies To Achieve Success In Your Regulatory Inspection
- Establishing Turnkey Tech Transfer Processes For Drug Product
- Achieving Accelerated Tech Transfer For A COVID-19 Program
- Mitigating Risks Associated With Single-Use Systems: Critical Considerations
WEBINARS
-
![iStock-1140779754-lab-team-research-equipment]( "Continuous Manufacturing Technology To Existing Process: Challenges And Advantages Of Implementing N-1 Perfusion Technology")
Discover key considerations and challenges in implementing N-1 perfusion technology, as well as the impact of continuous technology on tech transfer and process scale-up.
-
![Samsung3]( "Key Considerations When Outsourcing An Aseptic Fill/Finish Project To A CMO Partner")
This presentation addresses keys to outsourced drug production, including the importance of seeking the right partnerships to help overcome the challenges associated with secure commercial product supply.
-
![iStock-899692870-lab-microscope-PPE]( "What To Consider In Selecting The Best Cell Line To Accelerate The Timeline To IND")
Where reducing time to market can determine a key factor for a successful business, selecting the right pathway from the start is critical to prevent any future risks. Learn about what to consider in selecting the best cell line to accelerate speed to market.
-
![iStock-1219894348-cleanroom-PPE-lab-team]( "How COVID-19 Is Redefining Drug Development & Manufacturing")
Unprecedented challenging times provide opportunities for great advancements of innovation. Learn about utilizing the latest technology, establishing a robust business contingency plan, and eliminating lead time to deliver drugs.
-
![_92A0057-1-sized]( "Accelerated Tech Transfer From Development To Manufacturing For A COVID-19 Program")
The devastating effects of the COVID-19 pandemic can only be mitigated by the rapid development and manufacture of vaccines and neutralizing antibodies. This webinar describes the acceleration of tech transfer to enable kickoff to vial thaw for antibody manufacture within three months for a clinical program and within five months for a process qualification campaign.
-
![Samsung]( "Get To IND Faster")
How can you get to IND faster through an accelerated and high-performance proprietary cell line? Learn about a 3-month cell line development timeline and a high-quality cell line with outstanding productivity.
-
![Samsung]( "Biopharmaceutical Process Characterization")
Here we present process development and characterization strategies required to support commercial scale manufacture of antibody therapeutics.
VIDEOS
-
![Samsung]( "Driven. For Life.")
We are determined and resolute in our purpose: to be always dynamic, always responsible, and always innovative. It's in our DNA and it’s a part of who we are.
-
![Samsung]( "S-CHOice Cell Line Expression Technology")
Samsung Biologics proudly presents the official launch of their proprietary cell line, S-CHOice, a high-performing technology to start your successful therapeutics development journey. We can now offer our clients even more promising options in bringing their molecule faster and better to the market with world-class client satisfaction.
-
![Samsung]( "Building A Better Future")
Samsung Biologics’ vision is to enrich human life with technology and innovation. By continuously innovating our people, process, and portfolio, we will fulfill our mission to become the most trusted partner to our clients working together to achieve "Better Life" for humanity through biomedicines.
